Viking Therapeutics (VKTX) Misses Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Citi Starts Viking Therapeutic (VKTX) at Neutral
February 7, 2025 6:52 AM ESTCiti analyst David Lebowitz initiates coverage on Viking Therapeutic (NASDAQ: VKTX) with a Neutral rating and a price target of $38.00.
The analyst comments "The relatively recent emergence of GLP-1s for the treatment of obesity has rapidly established a megamarket opportunity... More
Viking Therapeutic (VKTX) PT Lowered to $95 at Truist Securities
February 6, 2025 12:07 PM ESTTruist Securities analyst Joon Lee lowered the price target on Viking Therapeutic (NASDAQ: VKTX) to $95.00 (from $120.00) while maintaining a Buy rating.
The analyst comments "4Q24 update narrowed timeline for the start of 2x Ph3 studies of SQVK2735 in obesity. Toplines from Ph3... More
